Quick Answer
COLLEGIUM PHARMACEUTICAL, INC reported Total Revenue of $780.57 million for fiscal year 2025.
COLLEGIUM PHARMACEUTICAL, INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $780.57M +23.6% |
$631.45M +11.4% |
$566.77M +22.2% |
$463.93M +67.6% |
$276.87M -10.7% |
$310.02M +4.5% |
| Revenue (ASC 606) | $780.57M +23.6% |
$631.45M +11.4% |
$566.77M +22.2% |
$463.93M +67.6% |
$276.87M -10.7% |
$310.02M +4.5% |
| Net Income | $62.87M -9.1% |
$69.19M +43.7% |
$48.16M +292.6% |
-$25.00M -135.0% |
$71.52M +167.3% |
$26.75M +217.7% |
| Diluted EPS | $1.73 -7.0% |
$1.86 +44.2% |
$1.29 +274.3% |
-$0.74 -139.8% |
$1.86 +144.7% |
$0.76 +211.8% |
| Total Assets | $1.66B -0.4% |
$1.66B +45.5% |
$1.14B -2.6% |
$1.17B +69.7% |
$692.08M +7.5% |
$643.84M +110.2% |
| Cash and Equivalents | $231.25M +227.7% |
$70.56M -70.5% |
$238.95M +37.6% |
$173.69M -6.8% |
$186.43M +7.1% |
$174.12M +2.4% |
| Stockholders Equity | $301.68M +31.8% |
$228.84M +17.1% |
$195.43M +0.3% |
$194.84M -4.0% |
$202.93M +9.1% |
$186.03M +112.8% |
| R&D Expense | — | $0.00 | $0.00 -100.0% |
$3.98M -57.9% |
$9.45M -3.3% |
$9.77M -5.5% |
| Operating Income | $179.64M +5.7% |
$169.90M +1.8% |
$166.96M +401.1% |
$33.32M +89.0% |
$17.63M -68.7% |
$56.23M +336.8% |
| Gross Profit | $463.26M +22.8% |
$377.34M +15.7% |
$326.17M +55.7% |
$209.49M +39.1% |
$150.62M -16.2% |
$179.84M +74.5% |
| Shares Outstanding | 31.71M +0.9% |
31.44M -1.3% |
31.87M -5.9% |
33.85M +0.6% |
33.66M -2.8% |
34.61M +2.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $209.36M | +31.4% | +11.4% |
| Revenue (ASC 606) | September 30, 2025 | $209.36M | +31.4% | +11.4% |
| Net Income | September 30, 2025 | $31.51M | +237.5% | +162.9% |
| Diluted EPS | September 30, 2025 | $0.84 | +211.1% | +147.1% |
| Total Assets | September 30, 2025 | $1.61B | -1.7% | +0.9% |
| Cash and Equivalents | September 30, 2025 | $150.10M | +285.3% | +27.9% |
| Stockholders Equity | September 30, 2025 | $274.81M | +17.3% | +18.3% |
| R&D Expense | June 30, 2022 | $0.00 | -100.0% | -100.0% |
| Operating Income | September 30, 2025 | $62.09M | +78.2% | +76.9% |
| Gross Profit | September 30, 2025 | $129.17M | +33.4% | +19.2% |
| Shares Outstanding | September 30, 2025 | 31.60M | -2.0% | +0.2% |
- COLLEGIUM PHARMACEUTICAL, INC reported Total Revenue of $780.57 million for fiscal year 2025.
- COLLEGIUM PHARMACEUTICAL, INC showed an increase of +23.6% in Total Revenue compared to the prior fiscal year.
- COLLEGIUM PHARMACEUTICAL, INC reported Revenue (ASC 606) of $780.57 million for fiscal year 2025.
- COLLEGIUM PHARMACEUTICAL, INC showed an increase of +23.6% in Revenue (ASC 606) compared to the prior fiscal year.
- COLLEGIUM PHARMACEUTICAL, INC reported Net Income of $62.87 million for fiscal year 2025.
- COLLEGIUM PHARMACEUTICAL, INC showed a decrease of -9.1% in Net Income compared to the prior fiscal year.
- COLLEGIUM PHARMACEUTICAL, INC reported Diluted EPS of $1.73 per share for fiscal year 2025.
- COLLEGIUM PHARMACEUTICAL, INC showed a decrease of -7.0% in Diluted EPS compared to the prior fiscal year.
- COLLEGIUM PHARMACEUTICAL, INC reported Total Assets of $1.66 billion for fiscal year 2025.
- COLLEGIUM PHARMACEUTICAL, INC showed a decrease of -0.4% in Total Assets compared to the prior fiscal year.
- COLLEGIUM PHARMACEUTICAL, INC reported Cash and Equivalents of $231.25 million for fiscal year 2025.
- COLLEGIUM PHARMACEUTICAL, INC showed an increase of +227.7% in Cash and Equivalents compared to the prior fiscal year.
- COLLEGIUM PHARMACEUTICAL, INC reported Stockholders Equity of $301.68 million for fiscal year 2025.
- COLLEGIUM PHARMACEUTICAL, INC showed an increase of +31.8% in Stockholders Equity compared to the prior fiscal year.
- COLLEGIUM PHARMACEUTICAL, INC reported R&D Expense of $0.00 for fiscal year 2024.
- COLLEGIUM PHARMACEUTICAL, INC reported Operating Income of $179.64 million for fiscal year 2025.
- COLLEGIUM PHARMACEUTICAL, INC showed an increase of +5.7% in Operating Income compared to the prior fiscal year.
- COLLEGIUM PHARMACEUTICAL, INC reported Gross Profit of $463.26 million for fiscal year 2025.
- COLLEGIUM PHARMACEUTICAL, INC showed an increase of +22.8% in Gross Profit compared to the prior fiscal year.
- COLLEGIUM PHARMACEUTICAL, INC reported Shares Outstanding of 31.71 million shares for fiscal year 2025.
- COLLEGIUM PHARMACEUTICAL, INC showed an increase of +0.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: